The paper, published in Frontiers in Neurology, highlights the potential of Spectris as a disease-modifying candidate for Alzheimer’s.
Cambridge, Massachusetts-based Cognito designed its non-invasive neuromodulation device to deliver proprietary gamma frequency light and sound stimulation. This evokes EEG-confirmed gamma frequency brain oscillations to treat central nervous system (CNS) diseases.
Spectris may reduce functional and cognitive decline and brain atrophy in individuals with mild-to-moderate Alzheimer’s. That includes specific reductions in white matter volume loss and myelin preservation. Cognito’s OVERTURE Phase 2 clinical trial reports on the ability of Spectris to preserve the corpus callosum in Alzheimer’s patients. The corpus callosum holds responsibility for information transfer between the brain’s hemispheres and plays a crucial role in maintaining cognitive function.
Cognito reported positive data from its separate OVERTURE II 12-month study earlier this year. The company also has a HOPE pivotal study evaluating the impact of daily, 12-month Spectris treatment. Cognito and Spectris featured on our list of 7 neurotech companies you need to know earlier this year.
Results from the six-month OVERTURE study demonstrated that daily active-treatment with Spectris demonstrated preservation of corpus callosum area whereas the sham-treated group exhibited notable atrophy. Investigators observed this as early as three months into treatment.
“The results highlight that preserving the structural integrity of the brain’s communication pathways could potentially slow cognitive decline and improve daily functioning,” said Dr. Ralph Kern, M.D., chief medical officer at Cognito Therapeutics. “This study supports Spectris as a potential disease-modifying therapy in Alzheimer’s, providing a different treatment modality beyond traditional drug-based approaches.”
